Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Presented at ASH in early December 2022, the KarMMa-2 Cohort 2c multicenter phase II trial examined idecabtagene vicleucel (ide-cel) for patients with relapsed and refractory multiple myeloma (RRMM) and for those with patients with MM who experienced early disease relapse after frontline therapy or poor therapeutic response after autologous stem cell transplant. Results showed minimal residual disease negativity for a subset of patients that was sustained for more than 18 months. Neurotoxicity and cytokine release syndrome developed in similar numbers of study patients as compared with those patients who received ide-cel in later lines.